Scanfil Group

January–June 2026

Scanfil Delivers a Strong Q2 as Strategic Progress Reshapes the Company

CEO Christophe Sut and CFO Iiris Heiskanen
16 July 2026


SCANFIL

Q2 2026 Highlights

Strong Customer Satisfaction

- Recommendation and loyalty (NPS) levels remained strong
- NPS was 50 (45 in Q2 2025)
- Average scores across key customer experience and quality areas reached a record high

Bruker AXS Division

- Bruker division AXS starts as a customer to Scanfil
- PCBAs, enclosures, and high-level assemblies from Scanfil's Mysłowice and Pärnu plants
- Strengthens Scanfil's growth strategy in Medtech & Life Science



EUR 25 Million New Agreement

- New customer with EUR 25 million of estimated annual turnover
- Customer is a leader in its field
- Scanfil production network will support the customer's global supply chain, manufacturing, and sustainability needs

Suzhou Expansion Started

- Investment of EUR 9 million
- Driven by a positive customer outlook
- Will increase the facility's area by 15,700 m^2, bringing the total area to nearly 37,000 m^2
- To be completed in mid-2027

Growth Accelerated and Profitability Increased

Q2 2026

MEUR 259.0 / 28.1%
Turnover / YoY, %

4.7%
Organic growth, %, YoY

MEUR 18.6 / 30.8%
Comparable EBITA, YoY

7.2% / 7.0%
Comparable EBITA-% / YoY

EUR 0.17 / 4.5%
EPS / YoY, %

- Strong contribution from acquisitions supported by solid organic growth
- Delivered inline with long-term target
- Momentum in organic growth continues to support our growth aspirations, EUR 72 million worth new deals won
- Good demand in Aerospace & Defense, Energy & Cleantech, and Medtech & Life Science
- Excellent organic growth in Americas
- EBITA margin improved by 0.2 pp from the last year

SCANFIL

Turnover and EBITA

Turnover



EBITA



Americas



Key takeaways in Q2:

- Organic turnover increased by 9.5%
- New product introductions (NPIs) are starting to contribute to sales and profit
- Successful ramp up of Atlanta's second SMT-line

APAC





Key takeaways in Q2:

- Investment of EUR 9 million in Suzhou plant expansion
- Doubling the size to nearly 37,000 m²
- Expected to be completed in mid-2027

Central Europe





Key takeaways in Q2:

- Organic turnover increased by 4.7%
- Polish operations delivered solid organic growth
- MB contributed strongly
- Restructuring of Germany operations ended

SCANFIL

Northern Europe





Key takeaways in Q2:

- Organic turnover increased by 5.5%
- Demand driven by Aerospace & Defense and Energy & Cleantech

Balanced Customer Portfolio





Aerospace & Defense

Turnover



Deals Won



Deals

1.0M€	Military
0.9M€	Military
0.1M€	Military
2.5M€	**In total**

Energy & Cleantech

Turnover



Deals Won



Deals

25.0M€	General
3.0M€	Energy saving solution
2.6M€	Control system
…	…
41.4M€	**In total**

SCANFIL

Industrial



Turnover



Deals Won



Deals

7.6M€	E-mobility
2.8M€	Housing & Building
0.9M€	Monitoring Solution
…	…
13.7M€	**In total**

SCANFIL

Medtech & Life Science

Turnover



Deals Won



Deals

6.3M€	Medical AI
3.2M€	Medical storage system
1.5M€	Breathing support
…	…
14.5M€	**In total**

SCANFIL

SCANFIL

Financials

CFO Iiris Heiskanen

Turnover and Comparable EBITA Bridge

Q2 2026
TURNOVER GROWTH (y-o-y)
EUR million



Q2 2026
Comparable EBITA (y-o-y)
EUR million



Turnover increased 28.1 %
- Strong contribution from acquisitions
- Organic growth was 4.7%, positive across all regions

Comparable EBITA EUR 18.6 million, margin 7.2%
- Increased in all regions
- Improvement was driven by turnover increase and good execution

Cash Flow and Net Working Capital





Operating cash flow EUR 5.9 million in H1 2026

- Working capital increased with volume growth
- Q2 cash flow improved Q/Q

Net working capital increased during H1

- Higher business volume, including acquisitions
- Accounts receivable increased Q/Q, while inventories decreased

Net Debt



Net debt at EUR 139.6 million

- Increased after acquisition financing and working capital increase
- Available liquidity remains strong, EUR 170.3 million in unused credit limits and loan facilities

Development of Key Figures

Equity Ratio, %



ROE, %



Net Gearing, %



Earnings per Share, EUR



Outlook for 2026

CEO Christophe Sut

Outlook for 2026

Guidance remains unchanged: turnover EUR 940–1,060 million and comparable EBITA EUR 64–78 million.

Solid operational execution, organic growth and major strategic steps in building company's future.

Focus areas:

- Drive good momentum in organic growth
- Investing in organic and in-organic growth
- Continue cost and inventory control

Q&A

Key Takeaways

- Scanfil delivered a strong turnover growth in Q2, way **above** its 10% **annual growth target**
- **Comparable EBITA margin strengthened** to 7.2% in Q2
- All regions delivered positive development, with particularly strong performance in the **Americas**
- **Aerospace & Defense** showed exceptional growth, supported by both organic performance and acquired capabilities
- **Energy & Cleantech** enjoyed a strong momentum with new significant EUR 25 million agreement and strong delivery on turnover in Q2

Contact information and analysts

CHRISTOPHE SUT, CEO
+358 407 318 411
christophe.sut@scanfil.com

IIRIS HEISKANEN, CFO
+358 44 788 2415
iiris.heiskanen@scanfil.com

PASI HIEDANPÄÄ, IR and Communications Director
+358 50 378 2228
pasi.hiedanpaa@scanfil.com

Carnegie AB, Stockholm
Marcus Develius
+46 70 848 85 67
marcus.develius@carnegie.se

Inderes Oyj
Antti Viljakainen
+358 44 591 2216
antti.viljakainen@inderes.fi

Nordea Oyj
Pasi Väisänen
+358 9 5300 5192
pasi.vaisanen@nordea.com

Disclaimer

Not to be published or distributed, directly or indirectly, in any country where its distribution or publication is unlawful. Forward looking statements: certain statements in this presentation may constitute "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Scanfil Plc to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this presentation, such statements use such words as "may," "will," "expect," "anticipate," "project," "believe," "plan" and other similar terminology. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of Scanfil Plc to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The forward-looking information contained in this presentation is current only as of the date of this presentation. There should not be an expectation that such information will in all circumstances be updated, supplemented or revised, except as provided by the law or obligatory regulations, whether as a result of new information, changing circumstances, future events or otherwise.